{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["116"],"submitter":["Bruhn M"],"pubmed_abstract":["<h4>Background</h4>Since the onset of the COVID-19 pandemic, SARS-CoV-2 neutralising monoclonal antibodies (mAbs) are being developed for clinical use. With the appearance of new virus variants, most mAbs lost their virus-neutralising activity, highlighting the complexity of mAb development under conditions of continuous SARS-CoV-2 evolution.<h4>Methods</h4>Hamsters were treated with SARS-CoV-2 neutralising mAbs and then challenged with SARS-CoV-2. Recombinant VSV expressing the spike protein of SARS-CoV-2 was utilised in an in vitro system to select for antibody escape variants. Surface plasmon resonance measurements were performed to characterise the binding affinity and epitope of various mAbs. Fc-mediated effector functions of neutralising and non-neutralising mAb combinations were det"],"journal":["EBioMedicine"],"pagination":["105770"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12148588"],"repository":["biostudies-literature"],"pubmed_title":["Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies."],"pmcid":["PMC12148588"],"pubmed_authors":["Salam A","Hinrichs I","Bartsch Y","Zimmer G","Kalinke U","Mirolo M","Baumgartner W","Reineking W","Mergani A","Osterhaus ADME","Gonzalez-Hernandez M","Obara M","Schambach A","Bruhn M"],"additional_accession":[]},"is_claimable":false,"name":"Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies.","description":"<h4>Background</h4>Since the onset of the COVID-19 pandemic, SARS-CoV-2 neutralising monoclonal antibodies (mAbs) are being developed for clinical use. With the appearance of new virus variants, most mAbs lost their virus-neutralising activity, highlighting the complexity of mAb development under conditions of continuous SARS-CoV-2 evolution.<h4>Methods</h4>Hamsters were treated with SARS-CoV-2 neutralising mAbs and then challenged with SARS-CoV-2. Recombinant VSV expressing the spike protein of SARS-CoV-2 was utilised in an in vitro system to select for antibody escape variants. Surface plasmon resonance measurements were performed to characterise the binding affinity and epitope of various mAbs. Fc-mediated effector functions of neutralising and non-neutralising mAb combinations were det","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-06-03T07:37:43.96Z","creation":"2026-04-26T03:10:17.89Z"},"accession":"S-EPMC12148588","cross_references":{"pubmed":["40403696"],"doi":["10.1016/j.ebiom.2025.105770"]}}